Főoldal > Videók

Keresés eredménye

Típusa:

rovat

Keresési paraméterek:

Videók

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!

EHA 2017 interview: Paul Cornes

Biosimilars for Hematologic Malignancies: The Path to Sustainable Care;

The role of biosimilars in promoting sustainability of care [presentation and panel discussion]...

EHA 2017 interview: Arnold G Vulto

A look at biosimilars development...

EHA 2017 interview: Susan Branford

Molecular Monitoring in the Setting of Deep Molecular Response and TFR...

EHA 2017 interview: Martin Dreyling

Acceptable therapeutic approach in relapsed/refractory Mantle Cell Lymphoma...

EHA 2017 interview: Iskra Pusic

IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A MULTICENTER OPEN-LABEL PHASE 2 STUDY(független ea)/ The results of a phase 2 clinical trial where chronic graft versus host disease (cGVHD) patients positively respond to ibrutinib...

EHA 2017 interview: Nitin Jain

IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)...

EHA 2017 interview: Alejandro Lazo-Langner

Data that can change the way cancer patients of 65 years and older are treated with anticoagulants, possibly preventing mortality...

EHA 2017 interview: Clemens Wendtner

Prioritizing therapies in CLL...

EHA 2017 interview: C Michel Zwaan

DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL...

EHA 2017 interview: Újdonságok a patológia szempontjából

Dr. Vida Lívia, az EHA 2017. évi kongresszusán foglalta össze részünkre a kongresszuson elhangzó újdonságokat a patológusok szemszögéből. Helyszíni interjúnkat a felvételre kattintva érhetik el!...

EHA 2017 interview: Paolo Ghia

"Patient assessment: Optimising the stratification of patients with CLL /

How does our understanding of signaling pathways inform treatment decisions? /

Future goals of treatment: Finite duration as a desirable goal(Janssen - Gilead)"...

EHA 2017 interview: Martin Griesshammer

RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL...

EHA 2017 interview: Peter Borchmann

GHSD HD18 study: reducing chemotherapy toxicity in advanced stage Hodgkin lymphoma...

EHA 2017 interview: Gilles Salles

New treatment for Lymphoma patients...

EHA 2017 interview: Shaji Kumar

DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT...

Újdonságok a veserákban

Az ESMO 2017. évi kongresszusán, Madridban Enrique Grande-val készítettünk interjút, aki a veserák kezelésének irányelveit foglalta össze. Tekintsék meg helyszíni interjúnkat!...